The global cellular starting materials market is estimated to be USD 1.45 billion in 2024 and is expected to reach USD 13.84 billion by 2035, with a CAGR of 22.77% during the forecast period 2025-2035. Growth in the market will be driven by the following factors: increasing demand for cell-based therapies; improvements in bioprocessing and manufacturing technologies; rising R&D investment; an increase in the prevalence of genetic disorders and chronic diseases; and supportive government initiatives and regulatory frameworks.
Advancements in cell culture, cryopreservation, and bioprocessing technologies have significantly enhanced the efficiency and scalability of producing cellular starting materials. These improvements have facilitated the generation of high-purity, consistent, and viable cells, thereby driving growth in the market. In November 2023, Charles River Laboratories introduced CliniPrime Cryopreserved Leukopaks, further expanding its suite of Good Manufacturing Practice (GMP)-compliant offerings for cell therapy development and manufacturing. This launch illustrates the ongoing innovation in the sector and its commitment to supporting the needs of cell therapy applications.
By product, the Leukopaks segment accounted for the highest revenue-grossing segment in the global cellular starting materials market in 2024 and is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for high-quality leukocytes for the development of cell-based therapies, immunotherapies, and cancer research. For instance, Charles River Laboratories and Navega Therapeutics, Inc. announced their partnership in March 2024. Through this partnership, Navega is able to manufacture adeno-associated virus (AAV)-based gene therapy by utilizing the current CDMO capabilities and advising services.
By grade, the good manufacturing practices (GMP) segment accounted for the highest revenue-grossing segment in the global cellular starting materials market in 2024 and is predicted to grow at the fastest CAGR during the forecast period owing to its stringent quality control standards, which ensure the safety, consistency, and efficacy of cellular products used in clinical and therapeutic applications. For instance, in September 2023, Sanguine Biosciences established a new qualified apheresis facility in Los Angeles, California, to collect concentrated white blood cell specimens.
By end-user, the pharmaceutical and biotechnology companies segment accounted for the highest revenue-grossing segment in the global cellular starting materials market in 2024 owing to the increasing investments in R&D for cell-based therapies, regenerative medicine, and biologics, as well as the expansion of drug discovery programs utilizing cellular starting materials. For instance, in June 2023, StemCyte signed a contract with a US-based company specializing in immune cell therapy to offer raw materials for allogeneic modified cell therapy. Additionally, the CMOs & CROs segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising trend of outsourcing cellular material production and processing services to contract manufacturing and research organizations to reduce operational costs and accelerate time-to-market for advanced therapies.
North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, strong presence of key biopharmaceutical companies, increased funding for cell-based research, and early adoption of advanced therapies, particularly in the U.S. and Canada. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rapidly expanding biotechnology sector, growing investments in R&D, supportive government initiatives for regenerative medicine, and increasing focus on personalized medicine and cell therapies, particularly in countries like China, Japan, and South Korea. For instance, the government stated in October 2023 that two cell and gene therapy hubs would be established in New York to boost cell therapy research and development.
This comprehensive research report focuses on the global and regional market size and forecasts from 2024 to 2035.
Advancements in cell culture, cryopreservation, and bioprocessing technologies have significantly enhanced the efficiency and scalability of producing cellular starting materials. These improvements have facilitated the generation of high-purity, consistent, and viable cells, thereby driving growth in the market. In November 2023, Charles River Laboratories introduced CliniPrime Cryopreserved Leukopaks, further expanding its suite of Good Manufacturing Practice (GMP)-compliant offerings for cell therapy development and manufacturing. This launch illustrates the ongoing innovation in the sector and its commitment to supporting the needs of cell therapy applications.
By product, the Leukopaks segment accounted for the highest revenue-grossing segment in the global cellular starting materials market in 2024 and is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for high-quality leukocytes for the development of cell-based therapies, immunotherapies, and cancer research. For instance, Charles River Laboratories and Navega Therapeutics, Inc. announced their partnership in March 2024. Through this partnership, Navega is able to manufacture adeno-associated virus (AAV)-based gene therapy by utilizing the current CDMO capabilities and advising services.
By grade, the good manufacturing practices (GMP) segment accounted for the highest revenue-grossing segment in the global cellular starting materials market in 2024 and is predicted to grow at the fastest CAGR during the forecast period owing to its stringent quality control standards, which ensure the safety, consistency, and efficacy of cellular products used in clinical and therapeutic applications. For instance, in September 2023, Sanguine Biosciences established a new qualified apheresis facility in Los Angeles, California, to collect concentrated white blood cell specimens.
By end-user, the pharmaceutical and biotechnology companies segment accounted for the highest revenue-grossing segment in the global cellular starting materials market in 2024 owing to the increasing investments in R&D for cell-based therapies, regenerative medicine, and biologics, as well as the expansion of drug discovery programs utilizing cellular starting materials. For instance, in June 2023, StemCyte signed a contract with a US-based company specializing in immune cell therapy to offer raw materials for allogeneic modified cell therapy. Additionally, the CMOs & CROs segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising trend of outsourcing cellular material production and processing services to contract manufacturing and research organizations to reduce operational costs and accelerate time-to-market for advanced therapies.
North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, strong presence of key biopharmaceutical companies, increased funding for cell-based research, and early adoption of advanced therapies, particularly in the U.S. and Canada. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rapidly expanding biotechnology sector, growing investments in R&D, supportive government initiatives for regenerative medicine, and increasing focus on personalized medicine and cell therapies, particularly in countries like China, Japan, and South Korea. For instance, the government stated in October 2023 that two cell and gene therapy hubs would be established in New York to boost cell therapy research and development.
This comprehensive research report focuses on the global and regional market size and forecasts from 2024 to 2035.
Report Scope:
- Base Year: 2024
- Forecast Period: 2025-2035
- Study Coverage
- Market Forecast by Product, Grade, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Cellular Starting Materials Market Report 2024 - 2035
Cellular Starting Materials Market Analysis & Forecast by Product 2024 - 2035 (Revenue USD Bn)
- Leukopaks
- Cells & Tissues
Cellular Starting Materials Market Analysis & Forecast by Grade 2024 - 2035 (Revenue USD Bn)
- GMP
- Research-use
Cellular Starting Materials Market Analysis & Forecast by End-User 2024 - 2035 (Revenue USD Bn)
- Pharmaceutical & Biotechnology Companies
- CMOs & CROs
- Academic & Research Institutes
Cellular Starting Materials Market Analysis & Forecast by Region 2024 - 2035 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Cellular Starting Materials Market: Product Estimates & Trend Analysis
8. Cellular Starting Materials Market: Grade Estimates & Trend Analysis
9. Cellular Starting Materials Market: End-User Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Cellular Starting Materials Market
12. Europe Global Cellular Starting Materials Market
13. Asia Pacific Global Cellular Starting Materials Market
14. Latin America Global Cellular Starting Materials Market
15. MEA Global Cellular Starting Materials Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Lonza Group
- STEMCELL Technologies
- Fisher Scientific
- Corning Incorporated
- Merck KGaA
- CellGenix
- PromoCell GmbH
- Thermo Fisher Scientific
- WuXi AppTec
- Charles River Laboratories
- Biospherix
- Medpace
- Sartorius AG
- StemBioSys, Inc.
- Haplogen GmbH
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | December 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 1.45 Billion |
| Forecasted Market Value ( USD | $ 13.84 Billion |
| Compound Annual Growth Rate | 22.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
